Figure 5.

DAF‐16 expression in pharynx suppress P. (a) Lifespan and (b) P frequency of daf‐16 null or isoform‐specific mutant in daf‐2(e1370) mutant background. N = 2 trials. (c) Lifespan and (d) P frequency of isoform‐specific overexpression in daf‐16;daf‐2(e1370) double mutant background. N = 2 trials. (e) Lifespan and (f) P frequency of daf‐16;daf‐2(m577) double mutant overexpressing daf‐16 isoforms in the pharynx. N = 2 trials. (g) Lifespan and (H) P frequency of daf‐16;daf‐2(e1370) double mutant overexpressing daf‐16 isoforms in the pharynx. N = 2 trials